Labcorp Oncology’s executives highlighted a shift toward paired germline and somatic testing in oncology, emphasizing how integrated testing can improve access to actionable biomarker insights. In an Executive Q&A, Rebecca Previs and Sarah Young described how the approach can support targeted-treatment selection and strengthen the clinical utility of testing workflows, including where AI may help streamline interpretation.